Navigation Links
AACR news: Studies show increasing evidence that androgen drives breast cancer
Date:4/10/2013

Estrogen and progesterone receptors, and the gene HER2 these are the big three markers and/or targets in breast cancer. Evidence presented at the AACR Annual Meeting 2013 adds a fourth: androgen receptors.

"This is a continuing line of work with all evidence pointing toward the addition of the androgen receptor as potential target and useful marker in all of the major subtypes of breast cancer," says Jennifer Richer, PhD, investigator at the University of Colorado Cancer Center and co-director of the CU Cancer Center Tissue Processing and Procurement Core.

The finding of androgen receptors (AR) as a potential target in breast cancer is especially important in light of its prevalence in breast cancers that don't express other hormone receptor targets or have developed resistance to treatments that target estrogen dependence. Overall, approximately 77 percent of breast cancers are positive for AR, including 88 percent of cancers that are estrogen receptor positive, 59 percent of those that are HER2 positive, and 20-32 percent of triple negative breast cancers.

The study presented this week explores the ability of estrogen-positive (ER+) breast cancers to develop resistance to anti-estrogen drugs by potentially developing an alternative addiction to AR and hypothesizes that anti-androgen therapy, such as the drug enzalutamide (formerly MDV3100) as successful counters to breast cancers' evolution. First, Richer and colleagues used breast cancer tumor registries to discover that cancers with higher ratios of AR to ER protein had shorter time to relapse after anti-estrogen therapies. Cut off from their estrogen addition, these cancers may have turned to growth and survival via androgens instead.

The group then returned to the lab to explore the effects of anti-androgen therapies in cell lines and preclinical models.

"Remarkably, the anti-androgen drug enzalutamide had effects comparable to the anti-estrogen drug tamoxifen in breast cancer cells that expressed both ER and AR," Richer says. HER2 cell lines that were also AR+ showed promising responses as well.

"We are excited to move toward clinical trials of anti-androgen therapies in breast cancer," Richer says. "And this study shows that patients with a high AR/ER ratio who relapse while on estrogen targeting therapies might be good candidates for this kind of therapy."


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
805-559-2023
University of Colorado Denver
Source:Eurekalert

Related biology news :

1. Good news: Fewer maternal and child deaths
2. REACH news: European ombudsman takes up PETA complaint
3. AACR news: Paragazole excels in preclinical models of triple-negative breast cancer
4. AACR news: Six2 homeoprotein allows breast cancer cells to detach and metastasize
5. AACR news: Little molecule makes big difference in bladder cancer metastasis
6. AACR news: New target plus new drug equals death of melanoma cells
7. AACR news: K9 osteosarcoma samples identify drivers of metastasis in pediatric bone cancer
8. AACR news: Misregulated genes common to tobacco-related cancers offer potential new prognostic tool
9. Studies reveal structure of EV71, a virus causing childhood illnesses
10. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
11. Autism Speaks awards $1.1 million to fund high priority studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):
(Date:5/19/2016)... MAPLE RIDGE, British Columbia , May 19, ... of AdvanTec Global Innovations Inc. (AGI), based out ... recently added Greenlane Biogas Ltd. to its ... a 2-year contract manufacturing agreement. AFS along with ... Bending Technologies (ABT) is a vertically integrated industrial ...
(Date:5/19/2016)... , May 19, 2016 ... and (OTC PINK: RGBPP) announced today initiation of ... first cord blood based cancer immunotherapeutic product leveraging ... application, Regen described a generation of cord blood ... by gene silencing.  The product in development will ...
(Date:5/18/2016)... ... May 18, 2016 , ... Shimadzu Scientific Instruments ... University of Toledo. This two-day camp will take place annually starting June 2016. ... of pharmaceutical sciences in preparation for a university academic program. , The ...
(Date:5/18/2016)... ... May 18, 2016 , ... Every day, more ... of asthma complications.* Costing more than $56 billion in direct costs annually, asthma ... “For too many, the suffering associated with uncontrolled asthma can be overwhelmingly disproportionate ...
Breaking Biology Technology: